Finally, we constructed a related risk score that divided NSCLC patients into high- and low-risk groups to accurately predict their clinical outcomes based on the features of SERPINE1, STC2, and LPCAT1. This evidence concerns the gene LPCAT1 and non-small cell lung carcinoma.